Eko Health Inc.
| Company type | Private |
|---|---|
| Industry | Health |
| Founded | 2013 |
| Founder |
|
| Headquarters | Oakland, CA |
Number of employees | 153 |
| Website | www |
Eko Health Inc. (Eko) is an American healthcare technology company that develops medical devices, software, and clinical support AI to aid in the detection of cardiovascular and pulmonary diseases.[1]
History
[edit]2013-2017: Founding and Early Innovations
[edit]Eko was founded in 2013 by Connor Landgraf, Jason Bellet, and Tyler Crouch. Landgraf was inspired to create Eko after seeing the limitations of traditional stethoscopes during his studies in biomedical engineering at the University of California, Berkeley and recruited his classmates Bellet and Crouch to join him.[2]
In 2015, Eko received FDA clearance for its first product, CORE, a digital attachment for traditional stethoscopes with a compatible smartphone application.[3]
In 2015, CORE was named one of TIME Magazine’s Best Inventions. [4]
In 2017, Eko received FDA clearance for the DUO, a combined digital stethoscope ECG that could be used without a traditional stethoscope.[5]
2018–2022: AI Development and Clinical Expansion
[edit]In 2018, Eko's low ejection fraction screening algorithm, developed with the Mayo Clinic, received a ‘Breakthrough Device’ designation from the FDA.[6]
In 2020, Eko announced $65 million in funding,[7] and a collaboration with 3M.[8] Eko raised an additional $30M in funding in 2022,[9] and received FDA clearance for its murmur analysis software.[10]
2023–Present: AI Adoption and Global Expansion
[edit]In 2023, Eko received FDA-clearance for the CORE500 digital stethoscope, which combines artificial intelligence (AI) software, high-fidelity audio, full-color display and 3-lead electrocardiogram (ECG). CORE500 offers compatibility with Eko’s Sensora platform, which uses artificial intelligence (AI) in cardiac disease detection. [11]
In April 2024, the company received FDA clearance for its low ejection fraction AI algorithm, developed in collaboration with the Mayo Clinic, enabling early detection of heart failure during routine physical exams.[12]
In June 2024, Eko secured $41 million in Series D financing, led by ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, to expand its AI-driven cardiac screening tools internationally.[13]
In November 2024, the American Medical Association (AMA) granted a Category III CPT code to Eko's Sensora AI platform. [14]
References
[edit]- ^ "Why Patience Was This Healthcare Company's Biggest Asset". Inc. Retrieved 29 May 2023.
- ^ "Take a Deep Breath, Then Check Your Smartphone". New York Times. 2 September 2015. Retrieved 29 May 2023.
- ^ "Smart stethoscope gets FDA stamp of approval". CNN. 2 September 2015. Retrieved 29 May 2023.
- ^ "Best Inventions of 2015". TIME Magazine. Retrieved 10 February 2024.
- ^ "Forbes Under 30 Alumni Score FDA Clearance For New Heart Monitor". Forbes. 7 June 2017. Retrieved 29 May 2023.
- ^ "New technology can screen for heart failure during routine physicals". CNBC. 23 December 2019. Retrieved 29 May 2023.
- ^ "Digital-Health Startup Eko to Expand With $65 Million Venture Financing". Wall Street Journal. 9 November 2020. Retrieved 29 May 2023.
- ^ "3M and Eko collaborate on stethoscopes". MassDevice. 19 October 2020. Retrieved 29 May 2023.
- ^ "Eko expands algorithmic heart problem detection and lands $30M Series C extension". TechCrunch. 22 March 2022. Retrieved 29 May 2023.
- ^ "Eko secures heart murmur AI clearance for digital stethoscopes". Fierce Biotech. 13 July 2022. Retrieved 29 May 2023.
- ^ "Eko launches digital stethoscope with heart disease detection AI". Mass Device. 27 June 2023. Retrieved 13 July 2023.
- ^ "Eko secures FDA clearance for stethoscope AI to catch low ejection fraction". Fierce Biotech. Retrieved 17 February 2025.
- ^ "Eko Health scores $41M to detect heart disease earlier and more accurately". TechCrunch. Retrieved 17 February 2025.
- ^ "Eko picks up reimbursement win for AI heart disease detection platform". Mass Device. Retrieved 17 February 2025.